Efficacy of sorafenib on metastatic renal cell carcinoma in Asian patients: results from a multicenter study
about
Incidence and risk of sorafenib-induced hypertension: a systematic review and meta-analysisHeme oxygenase-1 is a predictive biomarker for therapeutic targeting of advanced clear cell renal cell carcinoma treated with sorafenib or sunitinib.Efficacy and Safety of Sorafenib Therapy on Metastatic Renal Cell Carcinoma in Korean Patients: Results from a Retrospective Multicenter StudyEfficacy and safety of sorafenib versus sunitinib as first-line treatment in patients with metastatic renal cell carcinoma: largest single-center retrospective analysisCritical appraisal of sorafenib in the treatment of Chinese patients with renal cell carcinomaPrognostic factors for overall survival with targeted therapy in Chinese patients with metastatic renal cell carcinoma.Angiogenesis inhibitor therapies for advanced renal cell carcinoma: toxicity and treatment patterns in clinical practice from a global medical chart reviewSorafenib neoadjuvant therapy in the treatment of high risk renal cell carcinomaTargeted therapies for renal cell carcinoma in Chinese patients: focus on everolimus.A systematic review of the efficacy and safety experience reported for sorafenib in advanced renal cell carcinoma (RCC) in the post-approval setting.Clinical presentation and management of hand-foot skin reaction associated with sorafenib in combination with cytotoxic chemotherapy: experience in breast cancer.Prognostic analysis of Chinese patients with metastasis renal cell cancer receiving sorafenib: results from a multicenter long-term follow-up retrospective studyRetrospective Analysis of the Efficacy and Safety of Sorafenib in Chinese Patients With Metastatic Renal Cell Carcinoma and Prognostic Factors Related to Overall Survival.Clinicopathological and prognostic factors for long-term survival in Chinese patients with metastatic renal cell carcinoma treated with sorafenib: a single-center retrospective studyEvaluation of response from axitinib per Response Evaluation Criteria in Solid Tumors versus Choi criteria in previously treated patients with metastatic renal cell carcinoma.The Relationship Between the Adverse Events and Efficacy of Sorafenib in Patients With Metastatic Renal Cell Carcinoma: A Multicenter Retrospective Study from Northwest China.Key predictive factors for efficacy of axitinib in first-line metastatic renal cell carcinoma: subgroup analysis in Japanese patients from a randomized, double-blind phase II study.Anti-VEGF therapy in mRCC: differences between Asian and non-Asian patients.The risk of hand-foot skin reaction to axitinib, a novel VEGF inhibitor: a systematic review of literature and meta-analysis.Axitinib plasma pharmacokinetics and ethnic differences.Axitinib versus sorafenib as a second-line therapy in Asian patients with metastatic renal cell carcinoma: results from a randomized registrational studyPrognostic value of pathological features of primary lesion in metastatic renal cell carcinoma treated with sorafenib.A Phase II trial of dosage escalation of sorafenib in Asian patients with metastatic renal cell carcinoma.Clinical outcome and prognostic factors of sorafenib in Japanese patients with advanced renal cell carcinoma in general clinical practice.In-vivo relation between plasma concentration of sorafenib and its safety in Chinese patients with metastatic renal cell carcinoma: a single-center clinical study.Efficacy and safety of sorafenib in advanced renal cell carcinoma patients: Results from a long-term study.Efficacy of a protocol including heparin ointment for treatment of multikinase inhibitor-induced hand-foot skin reactions.
P2860
Q27003304-95CB6A8C-39D3-4729-87A1-888A01FEE99CQ27853203-3F1035B0-6CA6-47E6-A01B-C3D8AE0B01EAQ28547506-60163931-A61A-4430-AE99-1C9250500D73Q33430139-31B474A2-E5BC-46CD-BCA9-1F260F973198Q33754122-FD186B33-7BE2-4AD6-8F43-90553343D137Q34602155-BAE34136-FEFA-432C-9E1A-4442B11C4433Q34657590-274CE0AF-4FB4-421E-9FCD-729FB32AE874Q35043936-83D3906D-A83B-4F13-8E41-DFF199C037A5Q35063752-C47EBA6E-08CA-48ED-95A0-E8F386FE99B1Q35591889-3AA80926-78BE-4EA1-A055-9A13F10C2124Q35599769-21D26A70-6E53-431B-ADA5-4A60680515B3Q35811446-DD8C435B-0630-448E-A478-486ED7E02AF5Q36153108-DF32FB39-90B2-48CD-9A47-70A5B4E2A366Q36546814-1CE6C5A5-92FC-49F3-8FA9-976794A8CE88Q36907986-0E5AA2A0-1E1C-43F1-85B4-4AE390E712B1Q37226025-42F7C70F-4CB5-40FD-8270-D6D9EF910B0EQ37387563-829D3D91-8CDB-454E-B634-96EEC816489FQ37650644-39BF8980-B03F-43D9-8088-C3ECD0CFB028Q38076349-2F0AD7E7-6AF7-465A-9D5E-FC61538AA303Q38348548-5120718F-B1F1-4E5B-8682-46169850D341Q38531928-FD9FEDD8-AAF4-44C5-A812-EFCB3C5E2C4CQ38867811-F4285194-031D-4828-8F45-3582D5C694A4Q39100001-FFC74192-ECA7-4F4C-8BFA-4AB9FC5882A8Q39701786-9AA13681-45E4-48E2-830B-5DCAE8710AF7Q41092089-1647D6D4-3195-4775-95CD-B9ACA540BB75Q42014192-F3A4329F-6C91-4BBB-94EC-F9B166247112Q43785033-2ED1FAA5-5C77-452D-9719-0AD63C450140
P2860
Efficacy of sorafenib on metastatic renal cell carcinoma in Asian patients: results from a multicenter study
description
2009 nî lūn-bûn
@nan
2009 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Efficacy of sorafenib on metas ...... sults from a multicenter study
@ast
Efficacy of sorafenib on metas ...... sults from a multicenter study
@en
type
label
Efficacy of sorafenib on metas ...... sults from a multicenter study
@ast
Efficacy of sorafenib on metas ...... sults from a multicenter study
@en
prefLabel
Efficacy of sorafenib on metas ...... sults from a multicenter study
@ast
Efficacy of sorafenib on metas ...... sults from a multicenter study
@en
P2093
P2860
P356
P1433
P1476
Efficacy of sorafenib on metas ...... sults from a multicenter study
@en
P2093
Baijun Dong
Dingwei Ye
Hailiang Zhang
Jiade J Lu
Shilin Zhang
Xudong Yao
Yijun Shen
Yiran Huang
P2860
P2888
P356
10.1186/1471-2407-9-249
P407
P50
P577
2009-07-21T00:00:00Z
P5875
P6179
1052229704